Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Suven Life Sciences Ltd. Share Price
Day's Range
Day's Range
Low
₹230.60
High
₹245.95
Price Summary
| Previous Close | ₹233.55 |
|---|---|
| Day's Range | ₹230.60 - ₹245.95 |
| Open | ₹235.00 |
| 52 Week Range | ₹124.11 - ₹299.99 |
| Volume | 13,60,301 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 3,237.53 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -10.48 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 10.43 |
| PAT Margin (%) | -2415.11 |
| Face Value (₹) | 1.00 |
| ROCE(%) | -84.51 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 66.56 | 14.67 |
| Expenses | N/A | N/A |
| PBT | -470.8 | -439.44 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -470.8 | -439.45 |
About Suven Life Sciences Ltd.
| Founded | 1989 |
|---|---|
| Managing Director | Venkateswarlu Jasti |
| NSE Symbol | SUVEN |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,29,145.05 | 1,787.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,72,988.62 | 6,505.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,322.13 | 4,402.20 | 3,140.10 - 3,140.10 |
| Apollo Hospitals Enterprise Ltd. | 1,20,125.61 | 8,354.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,12,149.13 | 1,390.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,09,422.92 | 1,086.85 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,06,482.91 | 1,275.00 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,02,996.20 | 2,252.60 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 97,913.19 | 1,006.05 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,382.57 | 2,350.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Suven Life Sciences informs about press release
Suven Life Sciences informs about newspaper publication
Laurus Labs informs about AGM
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that it enclosed the Notice convening the 21st Annual General Meeting (‘AGM’) of shareholders of the Company, scheduled to be held on Thursday, July 2, 2026 at 3.00 pm (IST) through Video Conferencing (‘VC’)/ through Other Audio-Visual Means (‘OAVM’). The Notice of 21st AGM is also available on the Company’s website at www.lauruslabs.com.
The above information is a part of company’s filings submitted to BSE.
Viyash Scientific informs about acquisition
Lupin informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Suven Life Sciences Ltd. is ₹233.55 as of 2026-06-08.
The market capitalisation of Suven Life Sciences Ltd. is ₹6,169.74 as of 2026-06-08.
The 1-year return of Suven Life Sciences Ltd. is 0.00% as of 2026-06-08.
The P/E ratio of Suven Life Sciences Ltd. is 0.00 as of 2026-06-09.
The 52-week high and low of Suven Life Sciences Ltd. are ₹299.99 and ₹124.11, respectively, as of 2026-06-08.
People Also Ask
Suven Life Sciences Ltd. did not merge with another company. In 2020, the company undertook a demerger, transferring its contract research and manufacturing services (CRAMS) business into Suven Pharmaceuticals Ltd., which became a separate listed entity.
Suven Pharmaceuticals shares continue to be listed and traded under the name Suven Pharmaceuticals Limited.
Suven Life Sciences Ltd. and Suven Pharmaceuticals Ltd. are separate listed entities. In 2020, Suven Life Sciences demerged its CRAMS business into Suven Pharmaceuticals. Post-demerger, Suven Life Sciences focuses on clinical-stage drug discovery, while Suven Pharmaceuticals operates in contract research and manufacturing services.
A fund managed by Advent International acquired a controlling stake in Suven Pharmaceuticals Ltd. through a transaction involving the purchase of shares from existing promoters and shareholders, subject to regulatory approvals.
Suven Life Sciences Ltd. is engaged in drug discovery and development, particularly in the area of Central Nervous System disorders. The company focuses on research related to conditions such as Alzheimer’s disease and dementia, with an emphasis on developing novel therapeutic molecules through clinical-stage research programmes.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
